Does the media refer more to EXEL or ALNY?

In the previous week, Exelixis had 2 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 20 mentions for Exelixis and 18 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.15 beat Exelixis' score of 0.72 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 10 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Alnylam Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, EXEL or BIIB?

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.38B 5.58 $782.57M $3.01 17.51 Biogen $9.89B 2.92 $1.29B $9.32 20.96

Is EXEL or BIIB more profitable?

Exelixis has a net margin of 35.08% compared to Biogen's net margin of 13.81%. Exelixis' return on equity of 39.89% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.08% 39.89% 30.23% Biogen 13.81% 12.83% 8.01%

Does the media prefer EXEL or BIIB?

In the previous week, Biogen had 1 more articles in the media than Exelixis. MarketBeat recorded 21 mentions for Biogen and 20 mentions for Exelixis. Exelixis' average media sentiment score of 0.72 beat Biogen's score of 0.41 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 10 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Biogen 6 Very Positive mention(s) 2 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to EXEL or UTHR?

In the previous week, Exelixis and Exelixis both had 20 articles in the media. Exelixis' average media sentiment score of 0.72 beat United Therapeutics' score of 0.36 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 10 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive United Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, EXEL or INCY?

Incyte has higher revenue and earnings than Exelixis. Incyte is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.38B 5.58 $782.57M $3.01 17.51 Incyte $5.36B 3.82 $1.29B $7.08 14.46

Is EXEL or INCY more profitable?

Exelixis has a net margin of 35.08% compared to Incyte's net margin of 26.71%. Exelixis' return on equity of 39.89% beat Incyte's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.08% 39.89% 30.23% Incyte 26.71% 26.66% 19.77%

Does the media prefer EXEL or INCY?

In the previous week, Exelixis had 8 more articles in the media than Incyte. MarketBeat recorded 20 mentions for Exelixis and 12 mentions for Incyte. Incyte's average media sentiment score of 0.79 beat Exelixis' score of 0.72 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 10 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Incyte 7 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor NBIX or EXEL?

In the previous week, Exelixis had 4 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 20 mentions for Exelixis and 16 mentions for Neurocrine Biosciences. Exelixis' average media sentiment score of 0.72 beat Neurocrine Biosciences' score of 0.38 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exelixis 10 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Exelixis (EXEL) Competitors

$52.70 +0.21 (+0.40%)

Closing price 04:00 PM Eastern

Extended Trading

$51.96 -0.74 (-1.40%)

As of 05:21 PM Eastern

Compare

EXEL vs. ALNY, BIIB, UTHR, INCY, and NBIX

Should you buy Exelixis stock or one of its competitors? MarketBeat compares Exelixis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Exelixis include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

How does Exelixis compare to Alnylam Pharmaceuticals?

Exelixis (NASDAQ:EXEL) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Exelixis presently has a consensus price target of $47.35, suggesting a potential downside of 10.15%. Alnylam Pharmaceuticals has a consensus price target of $463.13, suggesting a potential upside of 52.82%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.85

Exelixis has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market.

Exelixis has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Exelixis is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.38B	5.58	$782.57M	$3.01	17.51
Alnylam Pharmaceuticals	$3.71B	10.89	$313.75M	$3.66	82.80

In the previous week, Exelixis had 2 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 20 mentions for Exelixis and 18 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.15 beat Exelixis' score of 0.72 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	10 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	12 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exelixis has a net margin of 35.08% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Alnylam Pharmaceuticals	11.72%	85.76%	10.32%

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Alnylam Pharmaceuticals beats Exelixis on 11 of the 17 factors compared between the two stocks.

How does Exelixis compare to Biogen?

Exelixis (NASDAQ:EXEL) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

In the previous week, Biogen had 1 more articles in the media than Exelixis. MarketBeat recorded 21 mentions for Biogen and 20 mentions for Exelixis. Exelixis' average media sentiment score of 0.72 beat Biogen's score of 0.41 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	10 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Biogen	6 Very Positive mention(s)	2 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.38B	5.58	$782.57M	$3.01	17.51
Biogen	$9.89B	2.92	$1.29B	$9.32	20.96

Exelixis has a net margin of 35.08% compared to Biogen's net margin of 13.81%. Exelixis' return on equity of 39.89% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Biogen	13.81%	12.83%	8.01%

Exelixis has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Biogen has a beta of 0.2, meaning that its share price is 80% less volatile than the broader market.

85.3% of Exelixis shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Exelixis currently has a consensus price target of $47.35, indicating a potential downside of 10.15%. Biogen has a consensus price target of $215.81, indicating a potential upside of 10.48%. Given Biogen's stronger consensus rating and higher possible upside, analysts plainly believe Biogen is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39
Biogen	1 Sell rating(s)	13 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.52

Summary

Biogen beats Exelixis on 9 of the 16 factors compared between the two stocks.

How does Exelixis compare to United Therapeutics?

Exelixis (NASDAQ:EXEL) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

United Therapeutics has a net margin of 40.62% compared to Exelixis' net margin of 35.08%. Exelixis' return on equity of 39.89% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
United Therapeutics	40.62%	19.24%	17.25%

Exelixis has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

Exelixis currently has a consensus target price of $47.35, suggesting a potential downside of 10.15%. United Therapeutics has a consensus target price of $619.42, suggesting a potential upside of 12.65%. Given United Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe United Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

United Therapeutics has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.38B	5.58	$782.57M	$3.01	17.51
United Therapeutics	$3.17B	7.36	$1.33B	$27.09	20.30

In the previous week, Exelixis and Exelixis both had 20 articles in the media. Exelixis' average media sentiment score of 0.72 beat United Therapeutics' score of 0.36 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	10 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
United Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

85.3% of Exelixis shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 8.6% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

United Therapeutics beats Exelixis on 12 of the 16 factors compared between the two stocks.

How does Exelixis compare to Incyte?

Exelixis (NASDAQ:EXEL) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

In the previous week, Exelixis had 8 more articles in the media than Incyte. MarketBeat recorded 20 mentions for Exelixis and 12 mentions for Incyte. Incyte's average media sentiment score of 0.79 beat Exelixis' score of 0.72 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	10 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Incyte	7 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Positive

Incyte has higher revenue and earnings than Exelixis. Incyte is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.38B	5.58	$782.57M	$3.01	17.51
Incyte	$5.36B	3.82	$1.29B	$7.08	14.46

Exelixis currently has a consensus price target of $47.35, indicating a potential downside of 10.15%. Incyte has a consensus price target of $104.00, indicating a potential upside of 1.58%. Given Incyte's higher probable upside, analysts plainly believe Incyte is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39
Incyte	1 Sell rating(s)	12 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.36

Exelixis has a net margin of 35.08% compared to Incyte's net margin of 26.71%. Exelixis' return on equity of 39.89% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.08%	39.89%	30.23%
Incyte	26.71%	26.66%	19.77%

85.3% of Exelixis shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 16.2% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Exelixis has a beta of 0.41, meaning that its share price is 59% less volatile than the broader market. Comparatively, Incyte has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Summary

Exelixis and Incyte tied by winning 8 of the 16 factors compared between the two stocks.

How does Exelixis compare to Neurocrine Biosciences?

Neurocrine Biosciences (NASDAQ:NBIX) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Exelixis has a net margin of 35.08% compared to Neurocrine Biosciences' net margin of 21.55%. Exelixis' return on equity of 39.89% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	21.55%	19.79%	13.82%
Exelixis	35.08%	39.89%	30.23%

Neurocrine Biosciences has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by insiders. Comparatively, 2.6% of Exelixis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Exelixis had 4 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 20 mentions for Exelixis and 16 mentions for Neurocrine Biosciences. Exelixis' average media sentiment score of 0.72 beat Neurocrine Biosciences' score of 0.38 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exelixis	10 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Exelixis has lower revenue, but higher earnings than Neurocrine Biosciences. Exelixis is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	5.76	$478.60M	$6.49	25.25
Exelixis	$2.38B	5.58	$782.57M	$3.01	17.51

Neurocrine Biosciences currently has a consensus target price of $187.52, suggesting a potential upside of 14.43%. Exelixis has a consensus target price of $47.35, suggesting a potential downside of 10.15%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Neurocrine Biosciences is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.87
Exelixis	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.39

Summary

Neurocrine Biosciences beats Exelixis on 9 of the 16 factors compared between the two stocks.

Get Exelixis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXEL vs. The Competition

Export

Metric	Exelixis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$13.25B	$3.31B	$6.45B	$11.97B
Dividend Yield	N/A	2.36%	2.69%	5.32%
P/E Ratio	17.51	18.69	23.77	23.69
Price / Sales	5.58	174.00	488.66	87.22
Price / Cash	17.05	111.03	41.39	55.53
Price / Book	6.54	6.51	9.76	6.39
Net Income	$782.57M	$24.09M	$3.56B	$337.36M
7 Day Performance	4.40%	-6.98%	-3.19%	-3.06%
1 Month Performance	18.64%	-3.57%	-0.12%	0.37%
1 Year Performance	24.38%	42.44%	25.26%	27.88%

Exelixis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXEL Exelixis	2.8528 of 5 stars	$52.70 +0.4%	$47.35 -10.1%	+24.3%	$13.25B	$2.38B	17.51	1,077	Insider Trade
ALNY Alnylam Pharmaceuticals	4.4046 of 5 stars	$295.50 -0.7%	$463.13 +56.7%	-0.5%	$39.45B	$4.29B	80.74	2,770	Positive News Analyst Forecast Insider Trade
BIIB Biogen	3.3947 of 5 stars	$193.08 -0.4%	$215.62 +11.7%	+49.0%	$28.51B	$9.94B	20.72	7,500	Trending News
UTHR United Therapeutics	4.2873 of 5 stars	$578.43 +1.8%	$619.42 +7.1%	+69.1%	$24.55B	$3.18B	21.35	1,400	Insider Trade
INCY Incyte	4.0298 of 5 stars	$97.10 -0.1%	$104.00 +7.1%	+50.2%	$19.40B	$5.14B	13.71	2,844	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXEL) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exelixis (EXEL) Competitors

EXEL vs. ALNY, BIIB, UTHR, INCY, and NBIX

How does Exelixis compare to Alnylam Pharmaceuticals?

Summary

How does Exelixis compare to Biogen?

Summary

How does Exelixis compare to United Therapeutics?

Summary

How does Exelixis compare to Incyte?

Summary

How does Exelixis compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXEL vs. The Competition

Exelixis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exelixis (EXEL) Competitors

EXEL vs. ALNY, BIIB, UTHR, INCY, and NBIX

How does Exelixis compare to Alnylam Pharmaceuticals?

Do analysts prefer EXEL or ALNY?

Which has more risk & volatility, EXEL or ALNY?

Which has higher earnings & valuation, EXEL or ALNY?

Does the media refer more to EXEL or ALNY?

Is EXEL or ALNY more profitable?

Do insiders and institutionals hold more shares of EXEL or ALNY?

Summary

How does Exelixis compare to Biogen?

Does the media prefer EXEL or BIIB?

Which has stronger earnings & valuation, EXEL or BIIB?

Is EXEL or BIIB more profitable?

Which has more risk and volatility, EXEL or BIIB?

Do insiders & institutionals have more ownership in EXEL or BIIB?

Do analysts prefer EXEL or BIIB?

Summary

How does Exelixis compare to United Therapeutics?

Is EXEL or UTHR more profitable?

Which has more volatility & risk, EXEL or UTHR?

Do analysts prefer EXEL or UTHR?

Which has better valuation and earnings, EXEL or UTHR?

Does the media refer more to EXEL or UTHR?

Do institutionals & insiders have more ownership in EXEL or UTHR?

Summary

How does Exelixis compare to Incyte?

Does the media prefer EXEL or INCY?

Which has stronger earnings and valuation, EXEL or INCY?

Do analysts recommend EXEL or INCY?

Is EXEL or INCY more profitable?

Do institutionals & insiders believe in EXEL or INCY?

Which has more risk and volatility, EXEL or INCY?

Summary

How does Exelixis compare to Neurocrine Biosciences?

Is NBIX or EXEL more profitable?

Which has more risk and volatility, NBIX or EXEL?

Do institutionals and insiders hold more shares of NBIX or EXEL?

Does the media favor NBIX or EXEL?

Which has preferable earnings & valuation, NBIX or EXEL?

Do analysts rate NBIX or EXEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXEL vs. The Competition

Exelixis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools